OneMedMarket is pleased to report that its member company Epion Health announced the closing of a $4.5M Series A financing round with Deerfield Management Company, a leading national venture fund.
“We are delighted to see Epion get funded. For the past three years, we’ve been saying that the future of the physician’s office is the iPad. The Epion application provides administrative support as well as patient education, making it the leader in this new space,” said Brett Johnson, CEO of OneMedMarket. “Epion first presented at OneMedForum in 2012, and we
Forum makes moves to an expanded venue for the launch of OneMedMarket.
OneMedForum announced that its 8th annual conference will move to the San Francisco Marriott Marquis, January 12-14, 2015. According to Brett Johnson, Founder and CEO, “This new venue is probably the most significant development in the nearly 8 years we’ve been doing the conference. Its central location and layout are ideal. It’s a perfect space for networking, partnering, exhibits, and company presentations occurring around a large central atrium. It offers a dramatic setting for the launch
NanoViricides, Inc. (NYSE MKT:NNVC) opened its new R&D and cGMP pilot manufacturing facility with U.S. Congressman Jim Himes performing the ribbon cutting to inaugurate the facility on July 21, 2014.
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The company’s novel nanoviricide® class of drug candidates is designed to specifically attack enveloped virus particles and dismantle them. The fully customizable manufacturing facility will enable cGMP to manufacture all nanoviricide® drug candidates in kilogram scale, sufficient for pre-IND and human clinical
On May 21, 2014, the first OneMedMarket conference was held in New York City. Accredited investors turned out from all over for presentations from eleven CEOs of curated, candidate healthcare technology companies. The presentations were webcast to over a hundred online watchers and private meetings were set up between CEOs and investors.
Each CEO was given eighteen minutes to present on their company to a room full of institutional, strategic, and private investors. It was never boring, with presentations from companies with novel cures for heart disease to revolutionary tools